Literature DB >> 4087954

Tentative dose-monitoring of doxorubicin in lymphoma patients.

J Robert, P Vrignaud, H Eghbali, T Nguyen-Ngoc, B Hoerni.   

Abstract

We have investigated the feasibility of individual dose-monitoring of doxorubicin in lymphoma patients. The purpose was to overcome the large variability of the early-phase kinetic parameters of the drug. We have used a test-dose and calculated for 32 patients a therapeutic dose which could allow us to obtain a predetermined early drug exposure. Such a predetermined drug exposure was obtained in 24 patients of the study. Important variations of the early clearance occurred in 8 patients.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4087954     DOI： 10.1007/BF02934911

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN： 0736-0118


  11 in total

1.  Induction chemotherapy of non-Hodgkin's malignant lymphomas. Preliminary results of a controlled trial.

Authors:  J Chauvergne; M Durand; B Hoerni; G Hoerni-Simon; R Brunet; C Lagarde
Journal:  Eur J Cancer       Date:  1977 Apr-May       Impact factor: 9.162

2.  Report of the Committee on Histopathological Criteria Contributing to Staging of Hodgkin's Disease.

Authors:  H Rappaport; C W Berard; J J Butler; R F Dorfman; R J Lukes; L B Thomas
Journal:  Cancer Res       Date:  1971-11       Impact factor: 12.701

3.  Early-phase pharmacokinetics of doxorubicin in non-Hodgkin lymphoma patients. Dose-dependent and time-dependent pharmacokinetic parameters.

Authors:  J Robert; B Hoerni; P Vrignaud; C Lagarde
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

4.  Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP.

Authors:  G Bonadonna; R Zucali; S Monfardini; M De Lena; C Uslenghi
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

5.  Early phase pharmacokinetics of doxorubicin (adriamycin) in plasma of cancer patients during single- or multiple-drug therapy.

Authors:  E Piazza; M G Donelli; M Broggini; C Sessa; N Natale; L Ottolenghi; S Marsoni; A Libretti; C Mangioni; L Morasca
Journal:  Cancer Treat Rep       Date:  1980 Aug-Sep

6.  [Pharmacokinetic study of doxorubicin in the treatment of malignant non-Hodgkin's lymphomas].

Authors:  J Robert; P Vrignaud; A Iliadis; H Eghbali; B Hoerni
Journal:  Nouv Rev Fr Hematol       Date:  1983

7.  High-dose methotrexate: preliminary evaluation of a pharmacokinetic approach.

Authors:  S Monjanel; J P Rigault; J P Cano; Y Carcassonne; R Favre
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

8.  Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function.

Authors:  R S Benjamin; C E Riggs; N R Bachur
Journal:  Cancer Res       Date:  1977-05       Impact factor: 12.701

9.  Dose response evaluation of adriamycin in human neoplasia.

Authors:  R M O'Bryan; L H Baker; J E Gottlieb; S E Rivkin; S P Balcerzak; G N Grumet; S E Salmon; T E Moon; B Hoogstraten
Journal:  Cancer       Date:  1977-05       Impact factor: 6.860

10.  Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response.

Authors:  J Robert; A Illiadis; B Hoerni; J P Cano; M Durand; C Lagarde
Journal:  Eur J Cancer Clin Oncol       Date:  1982-08
View more
  1 in total

1.  Pharmacokinetics of doxorubicin in sarcoma patients.

Authors:  J Robert; N B Bui; P Vrignaud
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.